Galapagos NV is a biotechnology company focused on the discovery and development of innovative treatments for a variety of diseases, particularly those affecting the immune system and the central nervous system
The company leverages its proprietary target discovery platform and extensive drug development expertise to create therapeutics that aim to address significant unmet medical needs. With a commitment to advancing science through collaboration and research, Galapagos-NV works towards bringing novel therapies from laboratory to clinic, ultimately striving to improve patient outcomes and quality of life.
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S., showed a 43% ORR and a median response duration of six months.
Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline.
Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees shares as deeply undervalued despite challenges, with new focus on CAR-T therapies under CEO Paul Stoffels.
Galapagos NV (NASDAQGLPG) announced the topline results from the DIVERSITY Phase 3 trial of filgotinib during induction and maintenance treatment of biologic-naïve and biologic-experienced patients with moderate to severe Crohn's disease (CD).
